NASDAQ:SVRA

Savara Stock Insider Trading

Healthcare > Biotechnology

Buy SVRA

*Your capital is at risk

$5.25

+0 (+0%)

At Close: Jun 03, 2026

Savara Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 48.09. In total, the insiders bought 6.99M and sold 1.16M SVRA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	48.09
● Buy	6.99M shares
● Sell	1.16M shares
71% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Dec 16, 2025 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 48.09. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 13, 2024 Sell	Common Stock F-InKind	Pauls Matthew Chief Executive Officer	CEO / President	92 593 Value: $297.2K
Dec 13, 2024 Sell	Common Stock F-InKind	Lowrance David L Chief Financial Officer	C-Suite Officer	24 350 Value: $78.2K
Dec 13, 2024 Sell	Common Stock G-Gift	Lowrance David L Chief Financial Officer	C-Suite Officer	12 000 Value: $0
Dec 13, 2024 Sell	Common Stock F-InKind	Erickson Anne Chief Business Officer	Officer	18 263 Value: $58.6K
Dec 12, 2024 Buy	Common Stock A-Award	Erickson Anne Chief Business Officer	Officer	100 000 Value: $335.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Erickson Anne Chief Business Officer	Officer	300 000 Value: $1.01M
Dec 12, 2024 Buy	Common Stock A-Award	Parker Braden C. Chief Commercial Officer	Officer	20 000 Value: $67.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Parker Braden C. Chief Commercial Officer	Officer	40 000 Value: $134.0K
Dec 12, 2024 Buy	Common Stock A-Award	Lutz Robert Matthew Chief Operating Officer	C-Suite Officer	100 000 Value: $335.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Lutz Robert Matthew Chief Operating Officer	C-Suite Officer	300 000 Value: $1.01M
Dec 12, 2024 Buy	Common Stock A-Award	Lowrance David L Chief Financial Officer	C-Suite Officer	100 000 Value: $335.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Lowrance David L Chief Financial Officer	C-Suite Officer	300 000 Value: $1.01M
Dec 12, 2024 Buy	Common Stock A-Award	Pratt Raymond Dennis Chief Medical Officer	Officer	80 000 Value: $268.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Pratt Raymond Dennis Chief Medical Officer	Officer	280 000 Value: $938.0K
Dec 12, 2024 Buy	Common Stock A-Award	Pauls Matthew Chief Executive Officer	CEO / President	400 000 Value: $1.34M
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Pauls Matthew Chief Executive Officer	CEO / President	900 000 Value: $3.02M
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Pratt Raymond Dennis Chief Medical Officer	Officer	280 000 Value: $938.0K
Dec 12, 2024 Buy	Common Stock A-Award	Pratt Raymond Dennis Chief Medical Officer	Officer	80 000 Value: $268.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Lowrance David L Chief Financial Officer	C-Suite Officer	300 000 Value: $1.01M
Dec 12, 2024 Buy	Common Stock A-Award	Lowrance David L Chief Financial Officer	C-Suite Officer	100 000 Value: $335.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Lutz Robert Matthew Chief Operating Officer	C-Suite Officer	300 000 Value: $1.01M
Dec 12, 2024 Buy	Common Stock A-Award	Lutz Robert Matthew Chief Operating Officer	C-Suite Officer	100 000 Value: $335.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Parker Braden C. Chief Commercial Officer	Officer	40 000 Value: $134.0K
Dec 12, 2024 Buy	Common Stock A-Award	Parker Braden C. Chief Commercial Officer	Officer	20 000 Value: $67.0K
Dec 12, 2024 Buy	Stock Option (Right to Buy) A-Award	Erickson Anne Chief Business Officer	Officer	300 000 Value: $1.01M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SAVARA INC

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas....

Read Full Profile Here